Exenatide is a subcutaneously injected, peptide GLP-1 receptor agonist that has been shown to improve glycaemic control, promote weight loss, and improve some cardiovascular risk markers in patients with T2DM [8,9]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.